Medications for Opioid Use Disorder in U.S. Jails and Prisons: Status Update | Bridge Therapeutics

Home
About Us
Resources
Team
News
Contact

26th March 2024

Medications for Opioid Use Disorder in U.S. Jails and Prisons: Status Update

Categories

Press Releases
Bridge In The News
Other News

For more information about Bridge Therapeutics please contact us today using the form below.

Investors Click HerePhysicians Click Here

CONTACT US

If you would like to learn more about Bridge Therapeutics please use the contact form below.

All fields marked with * are required.

217 Country Club Park
Ste. 325
Birmingham, AL, 35213

T: 877-223-6949

Bridge Therapeutics, Inc. is a development-stage pharmaceutical company pursuing FDA approval of BT‑219, a superior form of buprenorphine-naloxone for opioid use disorder (OUD), and approval of BT-205, a patented drug combination for the treatment of chronic pain in opioid-experienced patients (U.S. Patent #8410092).

© Copyright Bridge Therapeutics 2023. Bridge Therapeutics is a registered trademark of Bridge Therapeutics Inc.
All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.